| Literature DB >> 32046207 |
Evelyn Li Min Tai1,2, Yee Cheng Kueh3, Baharudin Abdullah2,4.
Abstract
Nasolacrimal duct obstruction (NLDO) is the most common cause of childhood epiphora. It is managed conservatively in the first year of life, after which surgical treatment is classically based on a stepwise paradigm of probing, intubation, and dacryocystorhinostomy. This systematic review aims to present the current role of intubation in the management of children with NLDO requiring surgical intervention. A search for English-language articles from the electronic databases PubMed, SCOPUS, and the COCHRANE library was conducted over a period of five months in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook. The following keywords were used to aid retrieval: stents, children, lacrimal intubation, endoscopic dacryocystorhinostomy, external dacryocystorhinostomy, NLDO, dacryocystitis, congenital, acquired. The primary outcome was defined as the success of the intervention, determined by resolution of symptoms and patency of the lacrimal anatomy confirmed by the fluorescein dye disappearance test or syringing. Secondary outcomes included the presence of complications. A total of 144 articles were identified; of these, 35 fulfilled the study criteria. The majority of the included studies involved lacrimal intubation alone, followed by intubation as an adjunctive procedure to balloon dacryoplasty and dacryocystorhinostomy. The overall success rate of these procedures ranged from 41.1% to 100%. Post-operative complications were reported in 65.7% of the included studies. Lacrimal intubation was most commonly performed as a primary procedure in children with NLDO, with high success rates. The main complication was stent dislodgement. There is lack of evidence regarding the benefit of intubation over probing as primary treatment of congenital NLDO. In the absence of high-quality evidence, the decision of whether to perform lacrimal intubation in children with NLDO requiring surgical intervention depends on clinical judgement and other low-level evidence, such as observational non-randomised trials.Entities:
Keywords: balloon dacryoplasty; children; dye disappearance test; endoscopic dacryocystorhinostomy; external dacryocystorhinostomy; lacrimal intubation; surgical intervention
Year: 2020 PMID: 32046207 PMCID: PMC7037191 DOI: 10.3390/ijerph17031067
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart.
Characteristics of the studies reviewed.
| Study Design | First Author, Year | Country | Procedure | Number of Patients|Number of Eyes | Mean Age in mo/yr | Gender in % (male) | Timing of Postoperative Stent Removal in d/wk/mo | Mean Follow–up in wk/mo (min–max) |
|---|---|---|---|---|---|---|---|---|
| Randomised controlled trials | Andalib, 2010 [ | Iran | LI | 57|70 | MCI: 34.9mo | NR | 3mo | NR |
| (13–71mo) | ||||||||
| BCI: 38.7mo | ||||||||
| (14–84mo) | ||||||||
| Andalib, 2014 [ | Iran | LI | 49|53 | MCI: 26.25mo | NR | 3mo | NR | |
| (13–49mo) | ||||||||
| PMCI: 26.85mo (16–68mo) | ||||||||
| Ceylan, 2007 [ | Turkey | LI | 20|24 (BCI) | 50.8mo (36–120mo) | NR | Average 6.2 mo | NR (12mo–NR) | |
| Elsawaby, 2016 * [ | Egypt | LI | 27|30 | 14.85mo | 50 | At least 3wk | 16wk (NR) | |
| (7–30mo) | ||||||||
| Kominek, 2010 [ | Czech Republic | LI | 83| 95 (Group 1: 42|48; Group 2:41|47) | NR (15–30mo) | NR | Group 1: 2mo | NR (NR–6mo) | |
| Group 2: 5mo | ||||||||
| Non–randomised controlled trials | Eshraghi, 2017a [ | Iran | LI | 99|99 (MCI:52|52; BCI:47|47) | 3.56yr | 57.6 | 3mo | NR (NR–12mo) |
| (1.3–10yr) | ||||||||
| Fayet, 2011 # [ | France | LI | 68|68 (Group 2:6|6; Group 3:62|62) | Group 2: NR | NR | Group 2: 39d Group 3: 29d | Group 2: 14wk (3–30wk) | |
| (1–9yr) | ||||||||
| Group 3: NR | Group 3: 16wk (3–74wk) | |||||||
| (1–6yr) | ||||||||
| Lee, 2012 [ | South Korea | LI | 46|60 (BCI:22|30; MCI:24|30) | BCI:23.3mo | 52.2 | BCI: 5–22wk | BCI: 16.4 wk (NR) | |
| (9–52mo) | ||||||||
| MCI: 23.1mo | MCI:5–15wk | MCI: 11.6 wk (NR) | ||||||
| (8–62mo) | ||||||||
| Kominek, 2011 [ | Czech Republic | LI | 53|70 (BCI:24|35; MCI:29|35) | NR (10–36mo) | 44.3 | 3–4mo | NR (NR–6mo) | |
| Eshraghi, 2017b [ | Iran | LI | 45|45 (LI only, study compared LI and probing) | 28mo (NR) | NR | Average 9.2 wk | NR (1wk–6mo) | |
| Retrospective with comparative groups | Al–Faky, 2012 $ [ | Iran | LI | 350|454 | 32.6mo | 46 | 3mo | 15.3mo |
| (12–132mo) | (3–108mo) | |||||||
| Kaufman, 1998 & [ | United States | LI | 64|73 (Prospective:39|48 | 31.8mo | NR | 4–6mo | NR (3–12wk) | |
| Retrospective:25|25) | (12–87mo) | |||||||
| Rajabi, 2016 [ | Iran | LI | 338|338 (Crawford:248|248; Monoka:52|52; Masteka:38|38) | NR | 56.1 | 3mo | Schedule follow up 3mo | |
| (1–4yr) | ||||||||
| Khatib, 2017 [ | United States | LI | 53|72 (complex; simple) | 22mo | NR | 2–3mo | 14mo | |
| (5–65mo) | (6–29mo) | |||||||
| Retrospective/prospective with single group/non–comparative/consecutive cases | Okumus, 2016 [ | Turkey | LI | 30|30 | 10.7yr | 60 | Average 4.6mo | 8.8mo |
| (7–15yr) | (6–16mo) | |||||||
| Orhan, 1997 [ | Turkey | LI | 16|18 | 25mo | 43.8 | 4–7mo | 12mo | |
| (18–48mo) | (4–24mo) | |||||||
| Eshraghi, 2014 [ | Iran | LI | 44|44 | 3.2yr (NR) | 45.5 | 2mo | 9mo | |
| (6.5–13mo) | ||||||||
| Ali, 2013 [ | India | ExtDCR | 10|11 | 9.4yr | 30 | 12–16wk | NR (3–6mo) | |
| (6–15yr) | ||||||||
| Engel, 2007 [ | United States | LI | 635|803 | 18mo | 45 | Median of 8wk | Median of 12wk | |
| (6.5–103.8mo) | ||||||||
| Dotan, 2015 [ | Israel | LI | 46|54 | 37.6mo (NR) | 52.2 | 4–6mo | NR | |
| El–Essawy, 2013 [ | Egypt | LI | 192|236 | 21.2mo | 51 | 3–6mo | 5mo (3–16mo) | |
| (8–48mo) | ||||||||
| Fayet, 2012 [ | France | LI | 88|110 | 2.4yr | NR | 3wk | 33.7wk (4–139wk) | |
| (1–8yr) | ||||||||
| Casady, 2006 [ | United States | LI | NR|7 | NR | NR | 3–3.5mo | NR (4–6wk) | |
| (12–18mo) | ||||||||
| Eloy, 2009 [ | Belgium | EDCR | 8|10 | 4.3yr | 87.5 | 1–3mo | 10.5mo | |
| (8mo–9yr) | (6–15wk) | |||||||
| Han, 2015 [ | South Korea | LI | 56|77 | 29.8mo | 53.6 | 2–3mo | NR | |
| (6mo–12yr) | ||||||||
| Nemet, 2008 [ | Australia | ExtDCR/ EDCR | 82|104 | 6.6yr (NR) | 51.2 | 6mo | 1.44yr (6mo–8yr) | |
| Napier, 2016 [ | United Kingdom | LI | 177|246 | 2.1yr (0–9.8yr) | 50.4 | At least 12wk | NR (6–12wk) | |
| Yazici, 2006 [ | Turkey | LI | 42|50 | 37.3mo | 47.6 | 3mo | 18.1mo | |
| (9mo–7yr) | (3–48mo) | |||||||
| Pelit, 2009 [ | Turkey | LI | 30|34 | 5yr (2–10yr) | 53.3 | 6mo | 40.32mo (12–96mo) | |
| Yalaz, 2004 [ | Turkey | LI | 26|29 | 4.85yr (2–12yr) | 46.2 | 6mo | 8.3mo (6–25mo) | |
| Fayet, 2010a [ | France | LI | 14|18 | 26.2mo (14–46mo) | NR | Average of 34d | 8.7wk (3–26wk) | |
| Pe, 1998 [ | United States | LI | 28|34 | 19.5mo (5mo–5yr 3mo) | 39.3 | 2–6mo | NR (NR) | |
| Fayet, 2010b [ | France | LI | 4|6 | 33mo (30–37mo) | NR | 3wk | NR (2–3mo) | |
| Huang 2009 [ | Taiwan | Balloon dacryocystoplasty and LI (MCI) | 25|33 | 3.5yr | 60 | 4–6mo | 6mo | |
| Five year record review (descriptive study) | Abdu, 2014 [ | Nigeria | ExtDCR | 17|NA | NR (NR–15yr) | 52.9 | 6wk | Up to 1yr |
Notes. * refer to group B, the intubation group; # Group 1 was excluded (aged over 16 years); $ comparison based on age groups; & comparison based on two different cohorts (prospective and retrospective groups had monocanalicular and bicanalicular silastic tube intubation respectively); MCI, monocanalicular; BCI, bicanalicular; PMCI, pushed monocanalicular; NR, not reported; d, day; wk, week; mo, month; yr, year; min, minimum; max, maximum; %, percentage; LI, lacrimal intubation; EDCR, endoscopic dacryocystorhinostomy; ExtDCR, external dacryocystorhinostomy.
Summary of reported outcomes.
| First Author, Year | Criteria for Successful Outcome | Overall Successful Outcome % | Post–Operative Complication |
|---|---|---|---|
| Andalib, 2010 [ | Munk score of 0 or 1 at 3 months after tube removal | MCI: 86.2 | None |
| BCI: 89 | |||
| Andalib, 2014 [ | Complete resolution of epihora at 3 months after tube removal | MCI: 90 | Slit punctum in PMCI |
| PMCI: 50 | |||
| Ceylan, 2007 [ | Complete remission of epiphora at 12 months, maintained for 4 months | 62.5 | Ocular irritation, false lumen in the inferior meatus, iatrogenic punctal laceration |
| Elsawaby, 2016 [ | Munk’s score 0 or 1 after 3 months from surgery | 83.3 * | Corneal ulcer, epistaxis |
| Kominek, 2010 [ | Fluorescein dye disappearance grade 0–1, corresponding to complete resolution of previous symptoms | Group 1(removal at 2 mo): 89.6 | None |
| Group 2 (removal at 6 mo): 91.5 | |||
| Eshraghi, 2017 [ | Dye disappearance test grade 0–1 & complete resolution of symptom at 12 months’ follow up | MCI: 59.6 | Loss of tubes |
| BCI: 74.4 | |||
| Fayet, 2011 & [ | Absence of epiphora, absence of mucous discharge | Group 2 (age 1–9 years): 100 | Group 2: none |
| Group 3 (age 1–6 years): 88.3 | Group 3: Loss of tube, keratitis | ||
| Lee, 2012 [ | Complete disappearance of symptoms | BCI: 93.3 | Tube prolapse, punctal slitting |
| MCI: 90 | |||
| Kominek, 2011 [ | Fluorescein dye disappearance test grade 0–1 = complete resolution from symptoms | BCI: 82.86 | Dislodging of tube, premature removal, loss of tube, slitting of punctum and canaliculi, granuloma pyogenicum, corneal erosion |
| MCI: 88.57 | |||
| Eshraghi, 2017b [ | Complete absence of clinical signs and symptoms of congenital nasolacrimal duct obstruction at 6 months after the procedure | 73.3 | Epiphora with tubes in place |
| Al–Faky, 2012 [ | Normal dye disappearance test, positive Jones primary dye test | 88 | NR |
| Kaufman, 1998 [ | Negative dye disappearance test | 79 | Bilateral preseptal cellulitis, migration of punctal anchor into canaliculus, corneal abrasion, corneal ulcer, premature removal of tube |
| Rajabi, 2016 [ | No sign and symptom of tearing or discharge | BCI:80.2 | Tube dislodging, spontaneous extrusion, corneal abrasion, punctual slitting due to cheese wiring, punctal plug migration to canaliculus |
| MCI:41.1 | |||
| Khatib, 2017 [ | Complete resolution of symptoms, negative dye disappearance test | 75 | Early tube loss |
| Okumus, 2016 [ | Complete resolution of previous signs and symptoms and DDT grade 0–1 | 73.3 | None |
| Orhan, 1997 [ | Resolution of symptoms and previous signs | 100 | Epiphora with tubes in place |
| Eshraghi, 2014 [ | Complete resolution or partial improvement | 82.6 | None |
| Ali, 2013 [ | Resolution of symptoms | 91 | NR |
| Engel, 2007 [ | Good clearance of fluorescein dye and/or absence of symptomatic testing | 96 | Conjunctival–corneal abrasion |
| Dotan, 2015 [ | Complete resolution of all preoperative CNLDO symptoms and signs | 85 | Spontaneous tube loss |
| El–Essawy, 2013 [ | Complete resolution of symptoms, no epiphora, no discharge, no increase tear lake | 82.2 | Cheesewiring of canaliculi, late postoperative granuloma formation |
| Fayet, 2012 [ | Absence of symptoms after stent removal or loss | 85 | Keratitis, tube loss, epiphora with tubes in place |
| Casady, 2006 [ | Complete resolution of symptoms | 100 | None |
| Eloy, 2009 [ | Complete resolution of symptoms | 90 | Transient slight epiphora |
| Han, 2015 [ | Disappearance of epiphora symptoms by a minimum of 2 months | 89.6 | Tube prolapse, tube loss |
| Nemet, 2008 [ | Objective confirmation of free fluorescein flow to the nose | 95.2 | Jones tube placement |
| Napier, 2016 [ | Complete resolution of symptoms and signs | 91.7 | NR |
| Yazici, 2006 [ | Resolution of lacrimal symptoms and signs, normal tear meniscus, and in cooperative patients, normal dye disappearance test and/or patent nasolacrimal duct on irrigation at the last examination. | 86 | Slit punctum |
| Pelit, 2009 [ | Complete resolution of previous lacrimal symptoms and signs | 100 | None |
| Yalaz, 2004 [ | Relief from symptom and/or positive results in fluorescein dye disappearance test | 93.2 (initial intubation); | Granuloma |
| 100 (reintubation) | |||
| Fayet, 2010a [ | Absence of epiphora, absence of mucous discharge | 88 | Mildly watery eye |
| Pe, 1998 [ | Easy, uncomplicated retrieval of the Prolene guide thread during intubation; complete resolution of previous signs and symptoms and a normal result of the dye disappearance test | 97 | None |
| Fayet, 2010b [ | Residual epiphora after ablation | 100 | None |
| Huang 2009 [ | Complete resolution of symptoms and normal dye disappearance test | 97 | None |
| Abdu, 2014 [ | Patent nasolacrimal duct 1 year after surgery | 88 | Extrusion of the tube, infection |
Notes. NNR, not reported; MCI, monocanalicular; BCI, bicanalicular; PMCI, pushed monocanalicular; * study consisted of probing and stent groups, the value refers to stent group; & study consisted of three groups; group 1 aged 44–77 years was excluded.
EPHPP quality assessment tool rating for individual studies.
| First Author, Year | Selection Bias | Study Design | Confounders | Blinding | Data Collection Methods | Withdrawals and Dropouts | Global Rating |
|---|---|---|---|---|---|---|---|
| Andalib, 2010 [ | S | S | S | W | S | S | M |
| Andalib, 2014 [ | S | S | S | W | S | M | M |
| Ceylan, 2007 [ | S | S | W | W | S | S | W |
| Elsawaby, 2016 [ | S | S | W | W | S | S | W |
| Kominek, 2010 [ | S | S | W | W | S | S | W |
| Eshraghi, 2017 [ | S | M | W | W | S | S | W |
| Fayet, 2011 [ | S | M | W | W | S | S | W |
| Lee, 2012 [ | S | M | S | W | S | S | M |
| Kominek, 2011 [ | S | M | W | W | S | S | W |
| Eshraghi, 2017b [ | S | M | W | W | S | S | W |
| Al-Faky, 2012 [ | S | M | W | W | S | NA | W |
| Kaufman, 1998 [ | S | M | W | W | S | S | W |
| Rajabi, 2016 [ | S | M | W | W | S | NA | W |
| Khatib, 2017 [ | S | M | W | W | S | NA | W |
| Okumus, 2016 [ | S | W | W | NA | S | S | W |
| Orhan, 1997 [ | S | W | W | NA | S | S | W |
| Eshraghi, 2014 [ | S | W | S | NA | S | S | M |
| Ali, 2013 [ | S | W | W | NA | S | S | W |
| Engel, 2007 [ | S | W | W | NA | S | NA | W |
| Dotan, 2015 [ | S | W | W | NA | S | NA | W |
| El-Essawy, 2013 [ | S | W | W | NA | S | NA | W |
| Fayet, 2012 [ | S | W | W | NA | S | NA | W |
| Casady, 2006 [ | S | W | W | NA | S | NA | W |
| Eloy, 2009 [ | S | W | W | NA | S | NA | W |
| Han, 2015 [ | S | W | W | NA | S | NA | W |
| Nemet, 2008 [ | S | W | W | NA | S | NA | W |
| Napier, 2016 [ | S | W | W | NA | S | NA | W |
| Yazici, 2006 [ | S | W | W | NA | S | NA | W |
| Pelit, 2009 [ | S | W | W | NA | S | NA | W |
| Yalaz, 2004 [ | S | W | W | NA | S | NA | W |
| Fayet, 2010a [ | S | W | W | NA | S | NA | W |
| Pe, 1998 [ | S | W | W | NA | S | NA | W |
| Fayet, 2010b [ | S | W | W | NA | S | NA | W |
| Huang 2009 [ | S | W | W | NA | S | NA | W |
| Abdu, 2014 [ | S | W | W | NA | S | NA | W |
Notes. EPHPP: Effective Public Health Practice Project; S: strong; M: medium; W: weak; NA: not applicable.